



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449	ATTY. DOCKET NO. 1662/63303	SERIAL NO. 10/802,627
	APPLICANT RUKHMAN et al.	
	FILING DATE March 17, 2004	GROUP 1626

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0443983 B1	February 12, 1991	EPO				
	00570091 A1	February 24, 1993	EPO				
	WO 01/82858 A2	November 8, 2001	PCT				
	WO 01/82858 A3	November 8, 2001	PCT				
	WO 02/06253 A1	January 24, 2002	PCT				
	WO 03/070246 A1	August 28, 2003	PCT				
	WO 03/089417 A1	October 30, 2003	PCT				
	WO 2004/026847 A1	April 1, 2004	PCT				
	WO 2004/094392 A1	November 4, 2004	PCT				
	WO 97/30036	August 21, 1997	PCT				
	WO 99/01459	January 14, 1999	PCT				
	WO 99/67231	December 29, 1999	PCT				
	WO 2005/089720 A1	September 29 2005	PCT				

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Buhlmayer, Peter, et al., Valsartan, A Potent, Orally Active Angiotensin II Antagonist Developed From The Structurally New Amino Acid Series, Bioorganic & Medical Chemistry Letters, 1994, Vol. 4, No. 1, pp. 29-34.
	Borka, Laszlo, Crystal Polymorphism of Pharmaceuticals, Acta Pharmaceutica Jugoslavica, 1990, pp. 71-94.
	Moenius, Th., et al., Carbon-14 Labelling of Diovan™ in its Valine-Moiety, Journal of Labelled Compounds and Radiopharmaceuticals, 2000, Vol. 43, pp. 1245-1252.
	Zhong Guo, et al. Chinese Journal of Pharmaceuticals, 2002, Vol. 32 Part 9, pp. 385-387.
	The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, 1996, pp. 1691.

EXAMINER /Susannah Chung/ (02/26/2009)	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	